Nyxoah (NASDAQ:NYXH) PT Raised to $14.00 at Cantor Fitzgerald

Nyxoah (NASDAQ:NYXHGet Free Report) had its target price hoisted by equities research analysts at Cantor Fitzgerald from $10.00 to $14.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 11.02% from the stock’s current price.

Other research analysts have also issued reports about the company. Piper Sandler boosted their target price on Nyxoah from $10.00 to $15.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Stifel Nicolaus decreased their target price on Nyxoah from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Nyxoah in a research note on Monday, December 11th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Read Our Latest Stock Report on NYXH

Nyxoah Stock Performance

Nyxoah stock opened at $12.61 on Friday. The business’s 50-day simple moving average is $6.14 and its 200 day simple moving average is $6.62. Nyxoah has a 12-month low of $4.00 and a 12-month high of $12.87. The company has a current ratio of 5.55, a quick ratio of 5.43 and a debt-to-equity ratio of 0.10.

Nyxoah (NASDAQ:NYXHGet Free Report) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.19. The firm had revenue of $1.06 million for the quarter, compared to analyst estimates of $1.50 million. Nyxoah had a negative return on equity of 38.46% and a negative net margin of 1,191.93%. On average, equities analysts predict that Nyxoah will post -1.65 EPS for the current fiscal year.

Institutional Trading of Nyxoah

A number of institutional investors have recently modified their holdings of NYXH. Invesco Ltd. bought a new stake in shares of Nyxoah during the 1st quarter valued at $8,177,000. Sei Investments Co. acquired a new position in shares of Nyxoah during the 2nd quarter worth $265,000. Millennium Management LLC acquired a new position in shares of Nyxoah during the 4th quarter worth $51,000. ExodusPoint Capital Management LP acquired a new position in shares of Nyxoah during the 1st quarter worth $97,000. Finally, AXA S.A. raised its holdings in shares of Nyxoah by 1.4% during the 1st quarter. AXA S.A. now owns 217,000 shares of the company’s stock worth $1,621,000 after buying an additional 3,000 shares in the last quarter.

Nyxoah Company Profile

(Get Free Report)

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

Read More

Analyst Recommendations for Nyxoah (NASDAQ:NYXH)

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.